[Federal Register Volume 69, Number 233 (Monday, December 6, 2004)]
[Notices]
[Pages 70470-70471]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-26736]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on September 20, 2004, Johnson 
Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, 
West Deptford, New Jersey 08066, made application by renewal to the 
Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)................  I
Difenoxin (9168)............................  I
Propiram (9649).............................  I
Amphetamine (1100)..........................  II
Methylphenidate (1724)......................  II

[[Page 70471]]

 
Codeine (9050)..............................  II
Oxycodone (9143)............................  II
Hydromorphone (9150)........................  II
Hydrocodone (9193)..........................  II
Morphine (9300).............................  II
Thebaine (9333).............................  II
Alfentanil (9737)...........................  II
Sufentanil (9740)...........................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative, 
Office of Liaison and Policy (ODLR) and must be filed no later than 
February 4, 2005.

    Dated: November 22, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-26736 Filed 12-3-04; 8:45 am]
BILLING CODE 4410-01-P